About: Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 25 May 2016

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2016 (ast) наукова стаття, опублікована в травні 2016 (uk) scientific article published on 25 May 2016 (en) مقالة علمية نشرت في 25 مايو 2016 (ar) գիտական հոդված հրատարակված 2016 թվականի մայիսի 25-ին (hy) artykuł naukowy opublikowany w Nature 25 maja 2016 (pl)
publication date	wds:Q37057914-532747BE-CD57-4217-A9AF-AA3EF85BA2DC
publication date	2016-05-25 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37057914-3ADCDF9B-94B1-44D2-85C3-55551764541E
language of work or name	English
exact match	wds:Q37057914-4515FED4-5691-466A-83DD-853398AA3A6E
exact match	https://scigraph.springernature.com/pub.10.1038/nature17960
cites work	wds:Q37057914-1B8D81F8-6F7B-412E-B764-32DBBDE2D424 wds:Q37057914-1FF5A36A-BA32-41CD-810A-21B073CDE138 wds:Q37057914-3A945E5D-8C62-4845-A2D9-48519C18AF5E wds:Q37057914-3EDDBFF4-C72A-4DD0-B5B1-9EB5B538D402 wds:Q37057914-5635A7FE-676B-4F0F-BB1D-6168BAFE7FDB wds:Q37057914-6F245294-F307-40D1-BB8D-C36EB788702E wds:Q37057914-74049F61-1A0D-4CD9-9418-56E954D61B89 wds:Q37057914-7DAB625C-CFA7-47D5-ACD0-E1E916F77565 wds:Q37057914-82926166-658F-48A0-8936-6FBEAAA2E85B wds:Q37057914-87DCD373-6FFF-448E-A16A-22980A39ADA1 wds:Q37057914-95841F92-A21B-426B-A676-B30E7CC902FA wds:Q37057914-C2A8B684-5B48-4C2B-A841-A51F18C9797C wds:Q37057914-CC961068-8BD9-4056-BF30-773606A3B288 wds:Q37057914-D254DCA3-B7A2-41BD-A1A8-B23D3D433395 wds:Q37057914-D9E750D9-2D1A-4D09-B565-766047C55A06 wds:Q37057914-DA5A76B0-62FE-4919-8DC3-2F0F84F72F9B wds:Q37057914-DA98DA35-55F8-4F13-87D3-840852486127 wds:Q37057914-DEEB9990-505C-4FE8-9E8A-C096C2B048FF wds:Q37057914-E1CC410E-9E81-4125-939B-D340B51DC24D wds:Q37057914-E1D46AD9-E001-4EC4-B629-7699E0DFE41A wds:Q37057914-E2F7B34F-EA44-45FD-BB7C-C498DF77DFD3 wds:Q37057914-E5611722-2D89-457A-91CF-88C54AA34788 wds:Q37057914-E5C17CDE-C8E7-4683-B215-A1BB618A7F0D wds:Q37057914-E85D7094-7684-40E5-B199-42D10E9D3AB6 wds:Q37057914-EBA8A755-2F66-43F7-8034-52455BCF3AA0 wds:Q37057914-ECD1F986-5389-4820-8494-8A6AAF83E10C wds:Q37057914-F6C93532-96EF-44BA-9B13-9A100B7B63BE wds:Q37057914-FB0DA5F3-0DE6-44F8-AFAD-0B5C7166E8D5 wds:Q37057914-FB30CAAB-7EAF-45E4-AA49-F1C51AC2C2E2 wds:Q37057914-FD633DAE-0A2A-4226-8FEB-07344AF2AE43
cites work	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer Rociletinib in EGFR-mutated non-small-cell lung cancer Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP The quest to overcome resistance to EGFR-targeted therapies in cancer Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy Mechanism for activation of mutated epidermal growth factor receptors in lung cancer A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines Evaluating the utility of the HTRF Transcreener ADP assay technology: a comparison with the standard HTRF assay technology. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity The clinical development of MEK inhibitors EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer
author name string	wds:Q37057914-042CE6C4-E397-4C13-852B-3A6E989B6E9C wds:Q37057914-0D66D0B3-46AC-4B0E-A5CB-EF36B4F92DDF wds:Q37057914-14B7798E-9C15-4BA4-A58F-B07FC2801E50 wds:Q37057914-160AD733-670C-402E-A4BA-380E61FD4315 wds:Q37057914-18AF7346-CD35-4843-A0CA-393F931251E2 wds:Q37057914-2ADA886F-E444-4012-B021-F774DF8C43A6 wds:Q37057914-2E90D413-53D4-4A39-8AE3-0BAFF97379B0 wds:Q37057914-405F689F-DAF8-413C-93ED-712F33449BCA wds:Q37057914-4C047694-CEB2-494B-9F1D-CDD1DB12E7B2 wds:Q37057914-53BE58F5-C5D3-43F0-AF7B-1D2525CF2F22 wds:Q37057914-64FDAB74-851C-49B7-AC3B-D9537AB900A1 wds:Q37057914-8490C7EC-CBF3-45FF-A623-7A947A580ED7 wds:Q37057914-87A3070C-E40E-487B-92B1-93BDC7ED14C5 wds:Q37057914-87DB4861-B30C-43AC-991B-570FC05E37CD wds:Q37057914-88706F71-A5ED-4F87-A42E-11A93E4F5122

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 194 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software